Kidney cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• HIF-1 0
• YAP 0
• AMPK 0
• MET 2
• B7-H3 2
• CTNNB1 0
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• IL-6 0
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 1,801 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery

  NCT07062952· Jinling Hospital, China· Updated 9 Nov 2026

  “The study was discontinued following a reassessment of the original protocol, which identified the need for substantial modifications to the study design and implementation. The original study was therefore considered unsuitable for continuation”Registry text, quoted unchanged. Source

• Terminated

  Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)

  NCT06005818· University of Alabama at Birmingham· Updated 3 Nov 2026

  “Loss of funding”Registry text, quoted unchanged. Source

• Terminated

  A Phase 1 Trial of ADI-270 in ccRCC

  NCT06480565· Adicet Therapeutics· Updated 27 Oct 2026

  “Sponsor decision”Registry text, quoted unchanged. Source

• Withdrawn

  Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)

  NCT07179770· NYU Langone Health· Updated 22 Oct 2026

  “PI Departure”Registry text, quoted unchanged. Source

• Terminated

  Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

  NCT03274258· M.D. Anderson Cancer Center· Updated 20 Oct 2026

  “The study met its prespecified futility criteria during the prespecified interim futility analysis after enrolling the first cohort of 10 patients.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

  NCT05879822· Incyte Corporation· Updated 20 Oct 2026

  “This was a strategic business decision. There were no safety concerns contributing to this decision.”Registry text, quoted unchanged. Source

• Suspended

  Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

  NCT06049576· City of Hope Medical Center· Updated 8 Oct 2026

  “09/29/2026 DSMC: Opened in order to apply suspension.”Registry text, quoted unchanged. Source

• Suspended

  Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

  NCT03575611· M.D. Anderson Cancer Center· Updated 6 Oct 2026

  “PI Request”Registry text, quoted unchanged. Source

• Withdrawn

  RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy

  NCT07218692· City of Hope Medical Center· Updated 1 Oct 2026

  “Study Abandoned withdrawn”Registry text, quoted unchanged. Source

• Withdrawn

  CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors

  NCT07297160· Baylor College of Medicine· Updated 16 Sept 2026

  “The study was revised into two separate protocols to separate treatments. We will submit as separate studies.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

  NCT00050752· National Cancer Institute (NCI)· Source

• A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Merck Sharp & Dohme LLC· Source

• Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

  NCT00026884· National Cancer Institute (NCI)· Source

• Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

  NCT05155033· National Cancer Institute (NCI)· Source

• Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer

  NCT00033137· National Cancer Institute (NCI)· Source

• Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer

  NCT07925333· Beth Israel Deaconess Medical Center· Source

• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

  NCT04586231· Merck Sharp & Dohme LLC· Source

• A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· Merck Sharp & Dohme LLC· Source

• Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

  NCT00001238· National Cancer Institute (NCI)· Source

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 36
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 94
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 11
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 76
• Positron-Emission Tomography 13
• Magnetic Resonance Imaging 60
• Machine Learning 70
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Ex vivo qualitative and quantitative analysis of fluorescently-labeled Hsp90 drug in human tumors.

  Cell Stress Chaperones, Nov 2025

• Epigallocatechin-3-gallate Sensitizes Human 786-O Renal Cell Carcinoma Cells to TRAIL-Induced Apoptosis.

  Cell Biochem Biophys, May 2015

• Combination of metformin and valproic acid synergistically induces cell cycle arrest and apoptosis in clear cell renal cell carcinoma.

  Int J Clin Exp Pathol, Mar 2015

• Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.

  PLoS One, Apr 2014

• Dietary selenium supplementation modifies breast tumor growth and metastasis.

  Int J Cancer, Jul 2013

• Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft.

  Urol Oncol, Jun 2011

• Melatonin sensitizes Caki renal cancer cells to kahweol-induced apoptosis through CHOP-mediated up-regulation of PUMA.

  J Pineal Res, Jan 2011

• Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins.

  Int J Oncol, Dec 2010

• A novel resveratrol analogue HS-1793 treatment overcomes the resistance conferred by Bcl-2 and is associated with the formation of mature PML nuclear bodies in renal clear cell carcinoma Caki-1 cells.

  Int J Oncol, Dec 2009

• EGCG inhibits growth and induces apoptosis in renal cell carcinoma through TFPI-2 overexpression.

  Oncol Rep, Mar 2009

See which targets of this disease your abstract mentions, and go to the people working on them.